Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$15K Sell
2,294
-5,906
-72% -$44.9K ﹤0.01% 1123
2023
Q4
$61K Sell
8,200
-2,100
-20% -$17.9K 0.01% 1326
2023
Q3
$104K Buy
+10,300
New +$219K 0.01% 1098

Other funds holding SLRN

Cutler Group's SLRN Position: Q1 2024 in Review

Cutler Group reduced its ACELYRIN (SLRN) stake by 72% in Q1 2024, selling an estimated $44.9K and leaving 2,294 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1123.

Cutler Group first reported a position in SLRN in Q3 2023 and has held it in 3 quarters since. The position peaked at $104K in Q3 2023. 109 funds tracked by Wall St. Rank hold SLRN as of Q1 2024.

  • Cutler Group held 2,294 shares of ACELYRIN worth $15K as of Q1 2024.
  • Cutler Group sold 5,906 ACELYRIN shares in Q1 2024, an estimated $44.9K.
  • ACELYRIN made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1123 holding.
  • Cutler Group first reported a position in ACELYRIN in Q3 2023 and has held it in 3 quarters since.
  • Cutler Group's ACELYRIN position peaked at $104K in Q3 2023.
  • 109 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.